Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C17H20N2O2S.ClH |
| Molecular Weight | 352.879 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCOC(=O)C1=C(N)SC2=C1CCN(CC3=CC=CC=C3)C2
InChI
InChIKey=LMAQHEGFQZGATE-UHFFFAOYSA-N
InChI=1S/C17H20N2O2S.ClH/c1-2-21-17(20)15-13-8-9-19(11-14(13)22-16(15)18)10-12-6-4-3-5-7-12;/h3-7H,2,8-11,18H2,1H3;1H
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.obatapasaja.com/2015/05/komposisi-dosis-dan-harga-nonflamin.html
http://www.ncbi.nlm.nih.gov/pubmed/702946
Curator's Comment: description was created based on several sources, including:
http://www.obatapasaja.com/2015/05/komposisi-dosis-dan-harga-nonflamin.html
http://www.ncbi.nlm.nih.gov/pubmed/702946
Tinoridine is a non-steroidal anti-inflammatory and analgesic agent. This agent has been proved pharmacologically to show antiedematous and analgesic actions. The mechanism of the anti-inflammatory action of Tinoridine is attributed to its biomembrane stabilizing action particularly on the lysosomes which are related to cell or tissue damage at the time of inflammation through the release of hydrolytic enzymes. Tinoridine may produce gastrointestinal disorders (nausea, loss of appetite, diarrhea, and constipation), vertigo drowsiness, dry mouth and itching.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | Nonflamin Approved UseTinoridine is indicated as anti-inflammatory agent after surgery injuries or injury in urology. |
|||
| Primary | Nonflamin Approved UseTinoridine is used to treat pharyngitis, laryngitis, tonsillitis. |
|||
| Primary | Nonflamin Approved UseFor analgesic purpose, Tinoridine is used to treat back pain. |
|||
| Primary | Nonflamin Approved UseFor analgesic purpose, Tinoridine is used to treat lumbago. |
|||
| Primary | Nonflamin Approved UseTinoridine is indicated to treat pain in chronic rheumatic diseases. |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
8.2 h CLINICAL TRIAL https://europepmc.org/article/med/6605310 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
TINORIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
8.2 h CLINICAL TRIAL https://europepmc.org/article/med/6605310 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
TINORIDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Disc. AE: Nausea, Appetite lost... AEs leading to discontinuation/dose reduction: Nausea Sources: Appetite lost Diarrhoea Constipation Vertigo Drowsiness Dry mouth Itching |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Appetite lost | Disc. AE | 100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Constipation | Disc. AE | 100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Diarrhoea | Disc. AE | 100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Drowsiness | Disc. AE | 100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Dry mouth | Disc. AE | 100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Itching | Disc. AE | 100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Nausea | Disc. AE | 100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Vertigo | Disc. AE | 100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Sample Use Guides
In Vitro Use Guide
Curator's Comment: Tinoridine, at concentrations from 5 microM up to 100 microM, produced a concentration-dependent inhibition on the simultaneous increases in lipid peroxide formation and renin release induced by 50 microM ascorbic acid in the renin granule fraction.
http://www.ncbi.nlm.nih.gov/pubmed/3906080
30 uM of Tinoridine HCl hydrochloride inhibited the Phospholipase C-induced lysosomal enzyme release from rat liver lysosomes.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID60947048
Created by
admin on Mon Mar 31 19:21:19 GMT 2025 , Edited by admin on Mon Mar 31 19:21:19 GMT 2025
|
PRIMARY | |||
|
100000084609
Created by
admin on Mon Mar 31 19:21:19 GMT 2025 , Edited by admin on Mon Mar 31 19:21:19 GMT 2025
|
PRIMARY | |||
|
246-103-6
Created by
admin on Mon Mar 31 19:21:19 GMT 2025 , Edited by admin on Mon Mar 31 19:21:19 GMT 2025
|
ALTERNATIVE | |||
|
24237-55-6
Created by
admin on Mon Mar 31 19:21:19 GMT 2025 , Edited by admin on Mon Mar 31 19:21:19 GMT 2025
|
NON-SPECIFIC STOICHIOMETRY | |||
|
DBSALT002331
Created by
admin on Mon Mar 31 19:21:19 GMT 2025 , Edited by admin on Mon Mar 31 19:21:19 GMT 2025
|
PRIMARY | |||
|
m1263
Created by
admin on Mon Mar 31 19:21:19 GMT 2025 , Edited by admin on Mon Mar 31 19:21:19 GMT 2025
|
PRIMARY | Merck Index | ||
|
SUB04880MIG
Created by
admin on Mon Mar 31 19:21:19 GMT 2025 , Edited by admin on Mon Mar 31 19:21:19 GMT 2025
|
PRIMARY | |||
|
CHEMBL592943
Created by
admin on Mon Mar 31 19:21:19 GMT 2025 , Edited by admin on Mon Mar 31 19:21:19 GMT 2025
|
PRIMARY | |||
|
05IIB89IVA
Created by
admin on Mon Mar 31 19:21:19 GMT 2025 , Edited by admin on Mon Mar 31 19:21:19 GMT 2025
|
PRIMARY | |||
|
247-342-9
Created by
admin on Mon Mar 31 19:21:19 GMT 2025 , Edited by admin on Mon Mar 31 19:21:19 GMT 2025
|
PRIMARY | |||
|
C100290
Created by
admin on Mon Mar 31 19:21:19 GMT 2025 , Edited by admin on Mon Mar 31 19:21:19 GMT 2025
|
PRIMARY | |||
|
25913-34-2
Created by
admin on Mon Mar 31 19:21:19 GMT 2025 , Edited by admin on Mon Mar 31 19:21:19 GMT 2025
|
PRIMARY | |||
|
134896
Created by
admin on Mon Mar 31 19:21:19 GMT 2025 , Edited by admin on Mon Mar 31 19:21:19 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
